The gene, mapping on chromosome 6, has been identified in 2002 in two parallel studies that classified CT2 as the sixth member of the OCT subfamily (Gong et al., 2002)
See the Melanotan II peptide profile for receptor detail
Who is an Ideal Candidate for PT-141
Ideal candidates might include those who: Have documented binge eating episodes causing significant distress Meet BMI criteria for weight management medications Have not responded adequately to psychological interventions (such as cognitive behavioural therapy) Do not have contraindications to GLP-1 therapy Understand the off-label nature of this indication UK SmPCs for GLP-1 medications note findings of thyroid C-cell tumours in rodent studies, though the relevance to humans remains uncertain
Further, over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide
The cost-per-gram of peptide active pharmaceutical ingredients (APIs) is significantly decreased by economies of scale made possible by large-scale manufacture